|
|
 |
|
Viewing report
|
|
|
|
Innovative Drug R&D in China
JZMed Inc., Oct 2009, Pages: 230
As Chinese pharmaceutical industry is rising rapidly, a growing number of Chinese drug companies pay attention to investing in research of innovative medicines. Their attempts are encouraged by government who promises to provide financial support and improve industry infrastructure. Their programs are infused with increasing numbers of returnees. Their progress is also accelerated by the growing abundance of venture capitals.
Their efforts have now started yielding fruitful results. There have been a variety of drug candidates in various development stages in the product pipelines of these Chinese drug companies for a broad range of therapeutic targets. More significantly, driven by a number of positive factors, this sector of the Chinese pharmaceutical industry has gained an extraordinary growth momentum and will thus continue to develop in the future.
However, to a large extent, it is still a myth to many companies/organizations outside China about the R&D activities in these Chinese drug companies and the progress of their programs.
The report “Innovative Drug R&D in China” is designed to reveal the real state of the innovative drug R&D in China including their research scope and scale, their current focus and capability in innovative drug R&D and the development stage of their product pipelines.
Based on a broad and in-depth investigation, the report provides a clear insight into the current situation of the innovative drug R&D in China. It also provides the in-depth analysis of the future growth potential and drivers of this Chinese industry.
The report is a must-read book to global pharmaceutical and biotech companies that are seeking research collaborations with Chinese companies, venture capital investors interested in investment opportunities in Chinese pharmaceutical and biotech industries, market research/consultancy companies seeking the information of the development situation of China’s drug R&D, and even the government agencies of those countries that are interested in learning the current and future development of China’s biotech industry.
Key Findings of the Report
- Largely due to the short history of its modern pharmaceutical industry, innovative drug R&D in China is just beginning, but it has truly taken off. The sustained fast growth of China’s economy has made the innovative drug research affordable to the country.
- At present there are three groups of companies playing key roles in this Chinese industry. The first group contains those top tier pharma companies. However, within this group of companies only a small fraction of them are conducting truly innovative drug R&D. The second group is composed of those young, R&D-oriented biotech companies. The majority of them are founded by returnees who received higher education in the West and further gained direct experience during their prolonged stay in the Western pharma or biotech industry. This is currently the main force of China’s innovative drug R&D. The third group includes those top tier state-owned research institutions including those research universities that have life science schools/departments.
- Interestingly, a small number of China-based outsourcing service providers (mainly those top tier CROs) are also conducting innovative drug R&D internally. On the other hand, the number of state-owned research institutes focusing on the innovative drug R&D is actually small. Our study revealed that it was only a perception that the top tier research institutions are the main force of the innovative drug R&D in China. In fact, the majority of these research institutions are primarily focusing on the basic type of medical research.
- The growing funding sources that now become more readily available to Chinese companies are the key driving force for their innovative drug R&D programs. Combined together, these companies support their R&D programs through four major funding sources: venture capitals, public offering (or IPO), government grants and self-funded (through either selling products or providing outsourcing services). The availability of government grants from both central and local provincial or municipal government is increasing. Opportunities of venture capital investment are also rapidly growing. Meanwhile, the exit channels for venture capital investment also gradually become mature.
- The current strengths of Chinese companies in research of innovative medicines almost equally reside in both small molecule and macro compound-based drugs. Their research approaches for small molecule drugs primarily focus on the structural modifications of natural products that are derived from the medicinal herbs of traditional Chinese medicines (TCMs). Their research methodologies for novel biologic drugs are, however, more diverse and advanced, including all types of biologically derived proteins.
- Nearly 65% of drug candidates are in early development stages (either preclinical or phase I clinical trials), an indication that the innovative drug R&D in China is just beginning. However, a decent number of novel medicines such as TCMs, gene therapy drugs and a variety of vaccines have proceeded to the advanced development stages. Some of them have been approved for marketing.
- Of all these Chinese drug R&D companies, about 45% of them either have programs for development of anti-cancer agents or entirely focus on the novel cancer drug development as their sole therapeutic area. Cancer drugs based on a variety of treatment mechanisms are also the largest group of drug candidates in their product pipelines. The situation is well in line with the current development state of the global drug R&D.
- The formation of a positive environment of innovative drug R&D in China also fosters the growing research activities in other pharmaceutical research areas such as the development of new drug delivery technologies, novel molecular diagnostic and imaging tools, biomarkers and frontier research such as stem cell and RNA interference. New technologies and products in these areas also start emerging.
- Largely attracted by the growth potential of China’s pharmaceutical market and the advantage of a large talent pool coupled with the still low labor cost, growing numbers of pharma and biotech companies from around the world are conducting innovative drug R&D in China or collaborating with local Chinese drug companies.
- However, the R&D collaborations between the major Chinese pharma companies and the R&D-oriented Chinese biotech companies are very rare. Unlike in the Western pharma industry, those major Chinese pharma companies do not rely on the emerging Chinese biotech companies to fill out their product pipelines. In fact, many of them do not have an established product pipeline filled with innovative medicines yet.
- Because of the short history in innovative drug R&D, there are a number of limitations associated with this Chinese industry primarily in such areas as the research skills and experience.
- On the other hand, driven by a number of factors, this sector of the Chinese pharma industry has gained an extraordinary growth momentum. The main growth driver is the determination of Chinese government to convert the Chinese pharmaceutical industry from a generic drug-focused industry to an innovation-driven drug development powerhouse.
Key Features of the Report
- The report is the first time ever in the history of pharmaceutical industry that describes in depth the most mysterious part of the Chinese pharmaceutical industry.
- The report depicted a whole picture of the innovative drug R&D in China at present. It revealed the real development state of this Chinese industry.
- The report also conducted in-depth analysis on the future development of this Chinese industry including all drivers and the roles each of them will play in steering this Chinese industry.
- The report contains forty (40) Chinese drug companies that have the most advanced programs in innovative drug research. It analyzed in depth the research focuses and capabilities and the product pipelines for each of these companies.
- The report also contains 110 drug candidates in various stages of preclinical and/or clinical development in the product pipelines of these Chinese companies. It described in detail the features of their molecular structure, the mechanisms of their action and the current stages of their development.
- The report is composed of four chapters (a total of 230 pages) and supported with 53 tables, 18 figures and 12 case studies. Each chapter focuses on one area and provides detailed and in-depth description and analysis.
- The report also contains a detailed company profile for each of these forty companies studied in the report.
- The report is currently the sole source available on the market to all types of companies and organizations that are interested in learning the development state of China’s innovative drug R&D.
Your Questions Are Answered
The report provides complete and detail answers to a variety of questions such as:
- What is the current state of China’s R&D on innovative medicines? How many companies are conducting innovative drug R&D in China?
- Who are the major players in China’s innovative drug R&D? How are their current R&D capabilities?
- What is the main driver encouraging Chinese companies to conduct research on innovative medicines?
- What are the major funding sources for innovative drug R&D programs in Chinese companies? To what extent are the Western VCs involved?
- What are the feasible exit strategies in China? Did they work? Which one is most popular at present?
- What is the development state of the product pipelines of these Chinese drug companies?
- What are the most active therapeutic areas currently pursued by Chinese companies? How do the drug candidates distribute in development stages of each therapeutic area?
- What are the strengths and weakness of Chinese companies in innovative drug R&D?
- What are the current state and capability of Chinese companies in the frontier pharmaceutical research areas?
- How about the research collaborations between domestic Chinese companies and between Chinese companies and experienced international pharma or biotech companies?
- What is the future prospect of China’s innovative drug R&D? What are the main drivers of its future development?
- Are there any Western companies that are interested in licensing drug candidates developed by Chinese companies?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
The New Trends of Global Pharmaceutical Outsourcing: New Developments in Strategy, Market, Service and Technology
China Pharma Outsourcing Annual Review 2011
Outlook of China Drug Formulation Market
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
Innovative Drug Discovery in Emerging Markets
Future Outlook of China Preclinical and Toxicology Outsourcing
China: The Key Pharmemerging Market - Deciphering Major Pharma Companies’ China Strategy
Comparison of Pharma Outsourcing between China and India
Chinese Biopharmaceutical Industry: Current State and Future
Global Prostate Cancer Therapeutics Market (2010 – 2020) (Opportunity Analysis, Pipeline Assessment & Market Forecast)
|
|
|
|
